Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.

Hsu JW, Yin PN, Wood R, Messing J, Messing E, Lee YF.

Oncotarget. 2013 Dec;4(12):2397-406.

2.
3.

Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.

Dovedi SJ, Kirby JA, Atkins H, Davies BR, Kelly JD.

J Urol. 2005 Jul;174(1):332-7; discussion 337.

PMID:
15947685
4.

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.

Bevers RF, Kurth KH, Schamhart DH.

Br J Cancer. 2004 Aug 16;91(4):607-12. Review.

5.

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S.

Oncotarget. 2016 May 10;7(19):27325-35. doi: 10.18632/oncotarget.8756.

6.

Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Luo Y, Han R, Evanoff DP, Chen X.

Clin Exp Immunol. 2010 Jun;160(3):359-68. doi: 10.1111/j.1365-2249.2010.04105.x. Epub 2010 Feb 10.

7.

Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.

Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, Yoshida H.

Int J Urol. 2007 Jun;14(6):532-8; discussion 538.

8.

Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.

Ajili F, Kourda N, Darouiche A, Chebil M, Boubaker S.

Ultrastruct Pathol. 2013 Feb;37(1):56-61. doi: 10.3109/01913123.2012.728688.

PMID:
23383616
9.
10.
11.

Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.

Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U.

J Urol. 2000 Aug;164(2):526-31.

PMID:
10893638
12.

Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.

Hori S, Miyake M, Tatsumi Y, Onishi S, Morizawa Y, Nakai Y, Tanaka N, Fujimoto K.

PLoS One. 2017 Apr 13;12(4):e0175494. doi: 10.1371/journal.pone.0175494. eCollection 2017.

13.

Activation of natural killer cells by Bacillus Calmette-Guérin.

Brandau S, Böhle A.

Eur Urol. 2001 May;39(5):518-24.

PMID:
11464031
14.
15.

Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.

Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A.

Clin Cancer Res. 2000 Sep;6(9):3729-38.

16.

A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.

Bunimovich-Mendrazitsky S, Claude Gluckman J, Chaskalovic J.

J Theor Biol. 2011 May 21;277(1):27-40. doi: 10.1016/j.jtbi.2011.02.008. Epub 2011 Feb 18. Erratum in: J Theor Biol. 2011 Jul 21;281(1):140.

PMID:
21334346
17.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28. Review.

PMID:
23628309
18.

Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stöckle M, Jocham D, Böhle A, Brandau S.

Cancer Res. 2006 Aug 15;66(16):8250-7.

19.

[Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].

Krajewski W, Kołodziej A, Dembowski J, Zdrojowy R.

Postepy Hig Med Dosw (Online). 2014 Mar 20;68:291-300. Review. Polish.

20.

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.

Gandhi NM, Morales A, Lamm DL.

BJU Int. 2013 Aug;112(3):288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Epub 2013 Mar 20. Review.

Supplemental Content

Support Center